A Dose Response Evaluation of SLITone Ultra HDM Mix Immunotherapy

Inclusion Criteria: * Aged 18 or older * Moderate to severe persistent HDM allergic rhinitis with or without asthma * Moderate to severe HDM allergic rhinitis symptoms during a baseline period * Positive skin prick test response (wheal diameter ≥ 3 mm) * Positive specific IgE ≥ IgE Class 2, ≥ 0.70 kU/l) Exclusion Criteria: * Previous treatment with immunotherapy with House dust mite immunotherapy * Ongoing treatment with any allergen specific immunotherapy product * Reduced lung function * Clinical history of uncontrolled asthma * Inflammatory conditions in the oral cavity with severe symptoms * History of anaphylaxis with cardiorespiratory symptoms * History of recurrent generalised urticaria * A history of drug induced facial angioedema or hereditary angiooedema * Any clinically relevant chronic disease (≥3 months duration) * Systemic disease affecting the immune system * Immunosuppressive treatment * Currently treated with tricyclic antidepressants; catecholamine-Methyltransferase inhibitors and mono amine oxidase inhibitors